Erasca, Inc. (ERAS) shares plummeted 5.05% in pre-market trading on Wednesday, continuing the downward pressure from recent clinical setbacks and legal challenges.

The decline follows Tuesday's 48% plunge after the cancer drug developer reported a patient death in a clinical trial. A 66-year-old man experienced severe lung inflammation approximately one month after starting Erasca's experimental therapy and passed away after treatment was halted. This contradicts the company's previous statements that its therapy was generally well-tolerated with mostly low-grade side effects.

Additionally, Erasca received a cease-and-desist letter from competitor Revolution Medicines Inc. on Monday, alleging that Erasca's cancer therapy infringes on certain elements of a Revolution Medicines patent. Analysts note that these developments have raised questions about the evolving safety profile and created near-term pressure on the stock until greater clarity emerges on both the clinical trial outcomes and the litigation trajectory.